Cullinan Therapeutics Inc (CGEM)
15.66
-2.41
(-13.34%)
USD |
NASDAQ |
Apr 19, 16:00
15.66
0.00 (0.00%)
After-Hours: 17:46
Cullinan Therapeutics Cash from Operations (TTM): -134.28M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -134.28M |
September 30, 2023 | -141.13M |
June 30, 2023 | -161.34M |
March 31, 2023 | -155.75M |
December 31, 2022 | -126.66M |
September 30, 2022 | -116.85M |
June 30, 2022 | -73.05M |
Date | Value |
---|---|
March 31, 2022 | -63.83M |
December 31, 2021 | -43.43M |
September 30, 2021 | -37.70M |
June 30, 2021 | -36.22M |
March 31, 2021 | -26.27M |
December 31, 2020 | -29.77M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-161.34M
Minimum
Jun 2023
-26.27M
Maximum
Mar 2021
-88.18M
Average
-73.05M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
Fate Therapeutics Inc | -132.26M |
Viking Therapeutics Inc | -73.38M |
Applied Therapeutics Inc | -55.17M |
Oscar Health Inc | -272.16M |
Edgewise Therapeutics Inc | -91.95M |